KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Construction in Progress (2016 - 2022)

Amgen has reported Construction in Progress over the past 14 years, most recently at $1.2 billion for Q4 2022.

  • Quarterly results put Construction in Progress at $1.2 billion for Q4 2022, up 22.9% from a year ago — trailing twelve months through Dec 2022 was $1.2 billion (up 22.9% YoY), and the annual figure for FY2022 was $1.2 billion, up 22.9%.
  • Construction in Progress for Q4 2022 was $1.2 billion at Amgen, up from $987.0 million in the prior quarter.
  • Over the last five years, Construction in Progress for AMGN hit a ceiling of $1.2 billion in Q4 2022 and a floor of $907.0 million in Q4 2019.
  • Median Construction in Progress over the past 5 years was $953.0 million (2018), compared with a mean of $995.0 million.
  • Biggest five-year swings in Construction in Progress: dropped 4.83% in 2019 and later increased 22.9% in 2022.
  • Amgen's Construction in Progress stood at $953.0 million in 2018, then dropped by 4.83% to $907.0 million in 2019, then rose by 0.88% to $915.0 million in 2020, then rose by 7.87% to $987.0 million in 2021, then increased by 22.9% to $1.2 billion in 2022.
  • The last three reported values for Construction in Progress were $1.2 billion (Q4 2022), $987.0 million (Q4 2021), and $915.0 million (Q4 2020) per Business Quant data.